Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 9/20 | 0.71 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 6/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.49 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | ALPG | P10696 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alagebrium SCHEMBL225618 | 0.98 | KMT2A (0.69) | KMT2APOLBOPRM1OPRD1MEN1 | |
| Alagebrium SCHEMBL1648822 | 0.98 | KMT2A (0.74) | KMT2APOLBOPRM1OPRD1MEN1 | |
| Bromide SCHEMBL3854076 | 0.90 | KMT2A (0.71) | KMT2APOLBOPRM1OPRD1MEN1 | |
| SCHEMBL6535467 | 0.86 | KMT2A (0.74) | KMT2APOLBOPRM1OPRD1MEN1 | |
| Bromide SCHEMBL3845600 | 0.84 | KMT2A (0.76) | KMT2APOLBOPRM1OPRD1MEN1 | |
| SCHEMBL6938197 | 0.84 | KMT2A (0.97) | KMT2APOLBOPRM1OPRD1MEN1 | |
| Bromide SCHEMBL5004646 | 0.84 | KMT2A (0.76) | KMT2APOLBOPRM1OPRD1MEN1 | |
| SCHEMBL6535048 | 0.84 | KMT2A (0.59) | KMT2APOLBOPRM1OPRD1MEN1 | |
| SCHEMBL6535058 | 0.83 | KMT2A (0.51) | KMT2APOLBOPRM1OPRD1MEN1 | |
| Bromide SCHEMBL5004644 | 0.83 | KMT2A (0.74) | KMT2APOLBOPRM1OPRD1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2085086-A2 | Method for treating congestive heart failure or diabetic nephropathy | Synvista Therapeutics, Inc. (US) | 2009-08-05 | — | — | EP | claimed |
| US-20090124674-A1 | Method for treating congestive heart failure | SYNVISTA THERAPEUTICS, INC. (US) | 2009-05-14 | — | — | US | claimed |
| US-20090124673-A1 | Method for treating diabetic nephropathy | SYNVISTA THERAPEUTICS , INC. (US) | 2009-05-14 | — | — | US | claimed |
| WO-2009051804-A1 | THIAZOLIUM COMPOUNDS FOR TREATING OR PREVENTING DISEASES ASSOCIATED WITH INSULIN RESISTANCE | SYNVISTA THERAPEUTICS, INC. (US) | 2009-04-23 | — | — | WO | claimed |
| WO-2009042213-A1 | METHODS OF TREATING OR PREVENTING CARDIAC DISEASE ASSOCIATED WITH A HIGH FAT DIET | SYNVISTA THERAPEUTICS, INC. (US) | 2009-04-02 | — | — | WO | claimed |
| US-20090088461-A1 | Methods of Treating or Preventing Cardiac Disease Associated With a High Fat Diet | SYNVISTA THERAPEUTICS, INC. (US) | 2009-04-02 | — | — | US | claimed |
| WO-2009023207-A1 | THIAZOLIUM COMPOUNDS FOR TREATING GASTROINTESTINAL COMPLICATIONS | SYNVISTA THERAPEUTICS, INC. (US) | 2009-02-19 | — | — | WO | claimed |
| US-7384625-B2 | Method and composition for rejuvenating hair, nails, tissues, cells and organs by ex-vivo or immersive treatment | FARINGTON PHARMACEUTICALS, LLC (US) | 2008-06-10 | — | — | US | claimed |
| EP-1353669-B1 | METHOD FOR TREATING GLAUCOMA | ALTEON INC (US) | 2007-08-15 | — | — | EP | claimed |
| US-20040235837-A1 | Method for treating fibrotic diseases or other indications IE | SYNVISTA THERAPEUTICS, INC. | 2004-11-25 | — | — | US | claimed |
| US-6713050-B2 | A THIAZOLIUM COMPOUND FOR TREATMENT OF HAIR, NAIL, EX-VIVO ORGAN, TISSUE OR CELLS BY IMPROVING THE DEFORMABILITY AND DIFFUSION COEFFICIENT OF HAIR, NAILS, TISSUES, CELLS, AND ORGANS IN HUMAN AND ANIMALS | FARRINGTON PHARMACEUTICALS, INC. | 2004-03-30 | — | — | US | claimed |
| US-RE38330-E1 | Preventing and reversing advanced glycosylation endproducts | ALTEON INC. | 2003-11-25 | — | — | US | claimed |
| EP-0808163-B1 | USE OF THIAZOLIUM COMPOUNDS FOR PREVENTING AND REVERSING THE FORMATION OF ADVANCED GLYCOSYLATION ENDPRODUCTS | ALTEON INC (US) | 2003-07-23 | — | — | EP | claimed |
| US-6506902-B2 | Alkylation of a thiazole compound | ALTEON, INC. | 2003-01-14 | — | — | US | claimed |
| US-20020182165-A1 | Method and composition for rejuvenating hair, nails, tissues, cells and organs by ex-vivo or immersive treatment | FARRINGTON PHARMACEUTICALS, LLC | 2002-12-05 | — | — | US | claimed |
| US-6440749-B1 | ADMINISTERING A THIAZOLE COMPOUND | ALTEON. INC. | 2002-08-27 | — | — | US | claimed |
| WO-2002056836-A2 | METHOD AND COMPOSITION FOR REJUVENATING HAIR, NAILS, TISSUES, CELLS AND ORGANS BY EX-VIVO OR IMMERSIVE TREATMENT | FARRINGTON PHARMACEUTICALS, LLC (US) | 2002-07-25 | — | — | WO | claimed |
| US-20020013471-A1 | Synthesis of thiazolium compounds | SYNVISTA THERAPEUTICS, INC. | 2002-01-31 | — | — | US | claimed |
| WO-2001072724-A1 | SYNTHESIS OF THIAZOLIUM COMPOUNDS | ALTEON, INC. (US) | 2001-10-04 | — | — | WO | claimed |
| US-6007865-A | FOR INHIBITING AND REVERSING NONENZYMATIC CROSS-LINKING (PROTEIN AGING), TREATING KIDNEY DAMAGE AND TREATING COMPLICATIONS OF DIABETES, PREVENTING FOOD SPOILAGE | ALTEON INC. | 1999-12-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088461-A1 | Methods of Treating or Preventing Cardiac Disease Associated With a High Fat Diet | FABP3, TXNRD2, PPARD | KMT2A 3186/4885POLB 3920/4885OPRM1 3618/4885 |
| US-20040235837-A1 | Method for treating fibrotic diseases or other indications IE | MMP1, COL1A1, COL2A1 | KMT2A 4599/4885POLB 2072/4885OPRM1 3301/4885 |
| US-20020182165-A1 | Method and composition for rejuvenating hair, nails, tissues, cells and organs by ex-vivo or immersive treatment | COL1A1, KRT18, COL2A1 | KMT2A 2711/4885POLB 417/4885OPRM1 4836/4885 |
| US-20090124673-A1 | Method for treating diabetic nephropathy | REN, SLC5A2, SLC5A1 | KMT2A 4493/4885POLB 3981/4885OPRM1 1647/4885 |
| US-20020013471-A1 | Synthesis of thiazolium compounds | THOC2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RIF1 | KMT2A 1729/4885POLB 3520/4885OPRM1 2326/4885 |
| US-20090124674-A1 | Method for treating congestive heart failure | TNNI3, TNNT2, FABP3 | KMT2A 4520/4885POLB 4353/4885OPRM1 1579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.